Overview
- The organizations announced a strategic collaboration that begins joint research and co-development work today.
- Teams are co-developing an advanced next-generation sequencing oncology test built on the SOPHiA DDM™ Platform.
- MD Anderson researchers will create AI-driven bioinformatics pipelines to help clinicians rapidly interpret RNA-sequencing results for diagnosis and treatment decisions.
- New programs will study tumor evolution in real time and improve the reliability and reproducibility of complex genomic testing across sites.
- The collaboration aims to better match patients to clinical trials, with MD Anderson efforts led by Shashikant Kulkarni, Ph.D., and J. Bryan, M.D., and SOPHiA GENETICS highlighting plans to scale access globally.